Biolexis Therapeutics
Biolexis Therapeutics, a biotech company, accelerates drug discovery with a unique chemical-biological approach and AI/ML platform, Moleculern™.
Founded
2021Biolexis Therapeutics, a biotech company, accelerates drug discovery with a unique chemical-biological approach and AI/ML platform, Moleculern™.
Biolexis Therapeutics, founded by cancer biologist Dr. David Bearss and medicinal chemist Dr. Hariprasad Vankayalapati, is a biotech company focused on accelerating drug discovery through a unique chemical-biological approach and an AI/ML platform called Moleculern™. The company specializes in developing small molecule therapeutics targeting cancers, metabolic, neurodegenerative, and autoimmune diseases. Their innovative AI-enabled process designs new chemical entities (NCEs) targeting various protein classes with unprecedented speed.
Notable figures affiliated with Biolexis Therapeutics include Dr. David Bearss and Dr. Hariprasad Vankayalapati, who together bring five decades of expertise in small molecule drug development and life science startups. The company has achieved significant milestones in its pipeline, demonstrating proof of concept for its AI-driven drug discovery process. Biolexis Therapeutics is making a substantial impact in the biotech industry by advancing the development of targeted therapies for complex diseases.
Companies similar to Biolexis Therapeutics include Empress Therapeutics, Biosim, Metis Therapeutics and 1910.
Biolexis Therapeutics was founded in 2021.
Biolexis Therapeutics' headquarters is located in American Fork, UT, US.
Biolexis Therapeutics' most recent funding round was for $10M (USD) in November 2023.
As of Nov 29, 2023, Biolexis Therapeutics has raised a total of $11.5M (USD).
Biolexis Therapeutics has 4 employees as of Feb 5, 2024.
Metis Therapeutics
metistx.com
